Bio-Matrix' Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in Anticipati...
June 06 2012 - 7:30AM
Marketwired
- World renowned experts to accelerate development of stem cell
therapeutics
- Regen anticipates new relationship with Clinartis to fast track
clinical studies
Bio-Matrix Scientific Group (OTCQB: BMSN) (PINKSHEETS: BMSN)
announced today that its Regen BioPharma unit has appointed three
internationally renowned regenerative medicine experts to its
Scientific Advisory Board (SAB). The new SAB members appointed are
David White, M.D., PhD; Wei-Ping Min, M.D., PhD and Vlad Bogin,
M.D.
Dr. White is a member of the Surgery and Immunology faculty of
The Schulic School of Medicine, University of Western Ontario. He
is one of the leading experts on using regenerative medicine
transplant procedures to treat pancreatic conditions, including
diabetes. He is also the Chief Scientific Officer of Sernova Corp
and was formerly a Therapeutic Area Head for Novartis. He received
the B.Sc. degree from the University of Surrey and the M.D. and PhD
degrees from Cambridge University.
Dr. Wei-Ping Min is Professor at the Lawson Health Research
Center in Canada. He is inventor of siRNA therapeutics in the area
of immunology and cell therapy to inhibit disease modalities. He is
also the founder/cofounder of several biotech companies including
MedVax Pharma Corp, and ToleroTech Inc. Dr. Min brings detailed
scientific and mechanistic expertise to Regen BioPharma. He earned
graduate and medical degrees from Nanchang University Medical
School and the PhD degree from Kyushu University.
Dr. Bogin is the President and CEO of Cromos Pharma, a contract
research organization that specializes in biopharmaceutical
clinical outsourcing. He was formerly the Director of Boehringer
Ingelheim in charge of the phase IV program for Dabigatran
Etexilate. He studied at the Yale University School of Medicine and
the University of Rochester School of Medicine and Dentistry.
Regen BioPharma has also entered into a Letter of Intent with
Clinartis LLC, a global contract research organization (CRO).
Clinartis is a full service global CRO serving pharmaceutical,
biotech and medical device companies to support Phase I - IV drug
and device clinical trials in the US and Europe.
The SAB and Clinartis will assist the Company in its acquisition
of intellectual property related to stem cells, translation of the
intellectual property into treatments, and optimizing the value of
these new therapies.
"The potential of regenerative medicine products is
significant," says Christopher Mizer, the President of Regen
BioPharma. "We believe that strategic collaborative relationships
between Regen BioPharma, our SAB and Clinartis will facilitate our
efforts to create value from that potential by developing
proprietary, life sciences technologies and demonstrating their
clinical utility."
"Our strong SAB has scientific and regulatory expertise, coupled
with Clinartis' access to world-class researchers and investigators
will be very instrumental for accelerated commercialization of the
cutting-edge biotechnology research on which Regen BioPharma is
focused," according to Bio-Matrix Scientific Group's Chairman &
CEO David Koos.
About Bio-Matrix Scientific Group Inc. and
Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS:
BMSN) is a biotechnology company focused on the development of
regenerative medicine therapies and tools. The Company is focused
on human therapies that address unmet medical needs. Specifically,
Bio-Matrix Scientific Group Inc. is looking to increase the quality
of life through therapies involving stem cell treatments. These
treatments are focused in areas relating to cardiovascular,
hematology, oncology and other indications.
Through Its wholly owned subsidiary, Regen BioPharma, it is the
Company's goal to develop translational medicine platforms for the
rapid commercialization of stem cell therapies. The Company is
looking to use these translational medicine platforms to advance
intellectual property licensed from entities, institutions and
universities that show promise towards fulfilling the Company's
goal of increased quality of life.
Disclaimer
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Bio-Matrix Scientific Group, Inc. David R. Koos,
PhD Chairman & Chief Executive Officer 619-702-1404 Email
Contact www.bmsn.us